Sign in
Taking people in GermanyPhase 1

Tests daraxonrasib with pembrolizumab in lung cancer with RAS mutations

Tests whether daraxonrasib with pembrolizumab is safe in adults with advanced RAS-mutated lung cancer.

Key facts

Who runs it
Revolution Medicines Inc.
Where
Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Immenhausen, and Moers, GermanySee the 7 sitesAlso in 4 other countries, 34 sites
Trial code
Registry title
A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Status
Recruiting
Phase
Phase 1
People taking part
180 people, planned
Started
17 Jul 2024
Expected to end
7 Oct 2027
Type of study
Interventional
Record updated
22 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-small cell lung cancer (NSCLC) that has certain RAS mutations. They get daraxonrasib with pembrolizumab, with or without chemotherapy.

Age
18 years or older, or the legal age of consent.
Sex
Men and women can join.
Disease stage
NSCLC with certain RAS mutations that is unlikely to be cured and has grown or spread to other body parts. At least one tumor lesion that can be measured.
Earlier treatment
People who have had prior cancer treatment, are not fit for standard treatments, or have no standard treatment available. Prior targeted therapy for a RAS mutation is not allowed.
Biomarker or test result
Certain RAS mutations in the lung cancer.

Main reasons for not taking part

  • Primary brain or spinal cord tumor spreading to other body parts
  • Stomach or bowel problems that may affect how daraxonrasib is absorbed
  • Major surgery in the last 4 weeks
  • Earlier targeted therapy for a RAS mutation
  • Other medical conditions, medicines or foods that may interfere with the study drugs

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients that are at least 18 years old or legal age of consent Patients that have NSCLC with certain RAS mutations. Patients that have NSCLC that is unlikely to be cured and has grown or spread to other body parts. Patients that have received prior cancer treatment, are not suitable for standard treatments, or no standard treatments are available.. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. Patients that have adequate organ function (bone marrow, liver, kidney)

Who cannot take part

  • Participants that have primary brain and spinal cord tumor spreading to other body parts. 2. Participants that have gastrointestinal problems that may affect absorption of daraxonrasib. 3. Participants that had any major surgery in the last 4 weeks. 4. Participants that have have previously taken targeted therapy for RAS mutation. 5. Participants that have any other medical condition that may interfere with the study drugs. 6. Participants that need other medicines, treatments or eating foods that may interfere with study drugs

Where in Germany

Also in 4 other countries, 34 sites

  • Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
  • University Hospital Cologne AöRCologne, GermanyTaking people
  • Technische Universitaet DresdenDresden, GermanyTaking people
  • Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
  • Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyTaking people
  • Lungenfachklinik ImmenhausenImmenhausen, GermanyTaking people
  • Stiftung Krankenhaus Bethanien Fuer Die Grafschaft MoersMoers, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the safety and tolerability of daraxonrasib in combination with pembrolizumab, with or without chemotherapy, in patients with advanced RAS- mutated NSCLC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1b/2 Open-Label, Multicenter Study of Daraxonrasib (RMC-6236) in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
Plain-language title
Tests daraxonrasib with pembrolizumab in lung cancer with RAS mutationsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 11 November 2026.
Record updated
22 September 2026